MRUS News and Press, Merus N.V. From 10/06/23

Mini Oral: MCLA-129 in combination with osimertinib in treatment naïve, and after progression on osimertinib, non-small cell lung cancer Poster: MCLA-129 in previously treated head & neck squamous cell carcinoma UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 06, 2023 (GLOB...

2023-09-26 10:50:17 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 26, 2023 – USA News Group –  The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an ...

2023-08-30 21:22:13 ET Summary Merus stock has cooled down after a strong rally, but long-term investors are sitting on a 47% gain since January. The company's pipeline includes promising clinical assets, but sentiment towards the stock is mixed and price structure has broken down...

2023-08-10 14:30:08 ET Merus ( NASDAQ: MRUS ) has priced an underwritten public offering to raise $150 million, the company said Thursday. The company will offer 6,818,182 common shares at $22 apiece. The offer price represents a 3.9% discount to Wednesday's closing p...

2023-08-09 16:19:53 ET Merus N.V. ( NASDAQ: MRUS ) plans to offer and sell its common shares through an underwritten public offering, the company said Wednesday. All of the common shares are being offered by Merus. The underwriters will have a 30-day option to pu...

2023-08-07 17:23:23 ET Merus press release ( NASDAQ: MRUS ): Q2 GAAP EPS of -$0.66 beats by $0.21 . Revenue of $10.48M (-17.4% Y/Y) misses by $0.89M . For further details see: Merus GAAP EPS of -$0.66 beats by $0.21, revenue of $10.48M misses by $0.89M

– Petosemtamab granted Fast Track Designation for the treatment of patients with recurrent or metastatic head & neck squamous cell carcinoma – Phase 3 trial of petosemtamab monotherapy in previously treated (2L/3L) head and neck squamous cell carcinoma planned to ini...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 28, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced tw...

– Zeno granted BTD for the treatment of NRG1+ non-small cell lung cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclo...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ) for cancer, today announced that the U.S...